(Incorporated in the Cayman Islands) 

We are a newly formed blank check company. We intend to focus our search for a target company on the drug development and health-tech sectors. We will look for companies involved in drug development and commercialization , as well as those involved in diagnostic and healthcare technology and firms in the service sector. We may pursue a target affiliated with RA Capital.

Matthew Hammond, PhD, a partner on RA Capital Management’s investment team, is our founding CEO and a director.

Henry Stusnick, our founding chief business officer and operating officer, is an analyst on the investment team at RA Capital Management.

Our sponsor is an affiliate of RA Capital Management, a leading life sciences focused investment firm with over $15 billion of regulatory assets under management as of December 31, 2025. Since its launch in 2002, RA Capital Management has focused primarily on the healthcare industry. 

(Note: Research Alliance Corp. III priced its stock-only SPAC IPO on May 19, 2026, in sync with the terms in the prospectus  – 7.5 million shares at $10.00 each – and raised $75 million, the company said. Background: Research Alliance Corp. III increased the size of its stock-only SPAC IPO to 7.5 million shares – up from 5.0 million shares initially – and kept  the price at $10.00 per share – to raise $75 million, according to its S-1/A filing dated May 13, 2026. Background: Research Alliance Corp. III  filed its S-1 for its SPAC IPO on March 24, 2026, and disclosed the terms of its stock-only SPAC: 5 million shares at $10.00 each to raise $50 million. Unlike most SPACs, Research Alliance III is not offering units consisting of a share of stock with either a warrant or a right attached.)